Biocon Q1FY27: Net Profit jumps 355% to Rs 141 Cr on Biopharma growth
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts more than Nifty Midcap 150 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon reported Q1FY27 total income of Rs 4,391 Cr, up 9% YoY. Operating revenue rose 10% to Rs 4,336 Cr, led by Biopharma growth of 17% (Biosimilars up 16% to Rs 2,855 Cr, Generics up 21% to Rs 760 Cr). Services revenue fell 16% to Rs 736 Cr. EBITDA grew 7% to Rs 902 Cr with margin flat at 21%. Net Profit surged 355% to Rs 141 Cr from a low base of Rs 31 Cr in Q1FY26, aided by lower interest costs (down 23%) and reduced exceptional items. Net Profit before exceptionals rose 245%.
Strong profit growth driven by Biopharma momentum and lower interest costs, though Services segment remains a drag. Sequential margins declined.